Long arginine 3-IGF-1, abbreviated as IGF-1 LR3 or LR3-IGF-1, is a synthetic protein and lengthened analogue of human insulin-like growth factor 1 (IGF-1).[1][2] It differs from native IGF-1 in that it possesses an arginine instead of a glutamic acid at the third position in its amino acid sequence (arginine 3), and also has an additional 13 amino acids at its N-terminus (MFPAMPLLSLFVN) (long), for a total of 83 amino acids (relative to the 70 of IGF-1).[2] The consequences of these modifications are that IGF-1 LR3 retains the pharmacological activity of IGF-1 as an agonist of the IGF-1 receptor, has very low affinity for the insulin-like growth factor-binding proteins (IGFBPs), and has improved metabolic stability.[1][2] As a result, it is approximately three times more potent than IGF-1,[3] and possesses a significantly longer half-life of about 2030 hours (relative to IGF-1s half-life of about 1215 hours).[4] IGF-1 LR3 Peptide is under active investigation in a number of cell culture and animal models
The dogs were acclimatized to the housing conditions for at least 7 days prior to the initiation of the experiment
Researchers study DSIP to investigate its potential roles in sleep modulation, stress response, pain control, and hormone secretion (LH, GH, ACTH)
Consistency between batches When you fill a Wegovy prescription at a retail pharmacy, every pen contains exactly the dose stated on the label
We're here to lay out exactly whats the difference between BPC 157 and BPC 159, based on the available science and our team's professional observations from years in this industry
